Testing TQA3038 Injection in Healthy Adults
Official title: A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics of TQA3038 Injection in Healthy Adult Subjects.
Run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT06085053 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new injection called TQA3038 in healthy adults to see if it's safe and how it works in the body, which could help treat chronic hepatitis B.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 54 (estimated) |
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Industry-sponsored |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06085053 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are healthy adults aged 18 to 60 with a BMI between 19 and 26 kg/m².
✕Probably not a fit
Patients with significant chronic or acute medical conditions or a history of drug or alcohol abuse may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase 1 clinical trial evaluates the safety and tolerability of TQA3038 injection in healthy adult subjects. Participants will receive either TQA3038 or a placebo through a single ascending dose administered subcutaneously. The study aims to assess pharmacokinetics and monitor any adverse effects following the injection. The focus is on understanding how the drug behaves in the body and its potential implications for treating chronic hepatitis B.
Why it matters
Potential benefit: If successful, this study could lead to a new treatment option for chronic hepatitis B.
How similar studies have gone: While this approach is novel in the context of TQA3038, similar studies assessing safety and pharmacokinetics of new drugs have shown success in the past.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female age 18～60 years. * Body mass index (BMI) 19 - 26 kg/m\^2. Exclusion Criteria: * Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation； * History or evidence of drug or alcohol abuse； * History of intolerance to SC injection；
Where it's running
-
Tongji Hospital
Wuhan, Hubei, China Recruiting
Study contacts
- Study coordinator: Dong Liu, Doctor
- Email: ld_2069@163.com
- Phone: +86 13507183749
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Impact of functional cure on patient-reported outcomes in chronic hepatitis B
This study tests whether people with chronic hepatitis B who achieve a functional cure have better patient-reported outcomes compared to those not cured, relapse, or healthy controls.
-
Sequential combination therapy for functional cure of chronic hepatitis B
This trial tests a new two-drug approach to see if adding immunotherapy to ongoing HBV treatment can lead to loss of hepatitis B surface antigen in adults with chronic hepatitis B.
-
Combination therapy for functional cure in chronic hepatitis B
This phase 2 trial tests whether a sequence of anti-PD-1/PD-L1 antibodies with pegylated interferon and nucleos(t)ide analogues can achieve functional cure (HBsAg loss) in adults with chronic hepatitis B.
-
GST-HG131/GST-HG141 tablets vs placebo in chronic hepatitis B
A phase IIa trial tests GST-HG131 and GST-HG141 tablets against placebo to see if they are safe and help people with chronic hepatitis B.
-
AHB-137 injection in people with chronic hepatitis B
This study tests AHB-137 vs placebo in adults with chronic hepatitis B who have not yet received antiviral treatment.
-
AHB-137 injection pharmacokinetics and safety in people with mild to moderate liver dysfunction and normal liver function
This study tests how AHB-137 behaves in the body and its safety in adults with chronic hepatitis B who have mild to moderate liver problems or normal liver function.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.